Digital
Sponsored
Innovation as Strategy: Enabling life sciences of the future
Innovation continues to drive the life sciences industry forward, …
19734 items found
News
Surprise Enhertu rejection follows NICE process change
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu …
R&D
Transitioning from traditional surgical methods to the innovative use of stem cells
Patient lives are being transformed by a transitioning from …
News
Novo Nordisk looks set to add another string to Ozempic bow
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet …
News
RYSE’s $50m digital health fund makes first investment
UK healthcare investor RYSE Asset Management has closed a new fund to …
Digital
Can creative analytics solve your D2C paid search headache?
Digitalisation has forever changed how we engage with healthcare. …
News
Ransom speculation as US reels from health cyberattack
As healthcare facilities and pharmacies try to recover from one of …
Oncology
Words matter: The power of language in cancer discussions
The priority for any individual diagnosed with cancer is to be …
News
Pharma’s Medicare counteroffers are all in, says HHS
On the heels of a setback in pharma’s legal attempts to block …
News
NICE backs frontline use of Jemperli in endometrial cancer
GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as …
R&D
Partner Content
4th mRNA-Based Therapeutics Summit
Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to …
R&D
Dark factories for a bright future
Much like medicine itself, drug manufacturing has evolved rapidly …
News
Novartis eyes year-end filing in US for Fabhalta in C3G
Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
Sales & Marketing
Enabling site success: Key insights to reducing burden and i...
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
LSX 2024 - Dr Tadaaki Taniguchi
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Less than three weeks away: Join Global Experts at Transderm...
11-12 November 2024 in London, UK
R&D
Partner Content
4th mRNA Analytical Development & Quality Control Summit | F...
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
